Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Thymoma 1Thymic epithelial tumor 1Stomach Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Hodgkin Disease 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 44Specimen Handling 44Biopsy 36Magnetic Resonance Spectroscopy 34Carboplatin 24Paclitaxel 23Nivolumab 20Gemcitabine 20Irinotecan 18Radiosurgery 16Cisplatin 14Pemetrexed 13Taxes 11Ipilimumab 11Fluorouracil 11Cetuximab 11trastuzumab deruxtecan 10olaparib 10Leucovorin 10130-nm albumin-bound paclitaxel 10abemaciclib 9Oxaliplatin 9Cyclophosphamide 9Capecitabine 9Bevacizumab 9palbociclib 8durvalumab 8Trastuzumab 8Fulvestrant 8ribociclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × AP 1903 reagent × 90 days × Clear all
NCT07509008 2026-05-05

Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
10 enrolled
Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡